Arcellx (ACLX) Stock Price, News & Analysis

Company Overview

Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region.

Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.

Key Stats

• Today's Range: $114.99 to $115.13
• 50-Day Range: $113.76 to $115.10
• 52-Week Range: $47.86 to $115.13
• Volume: 14.67 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $6.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $110.36
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 2/26/2026
• Today: 8/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACLX
• CIK: 1786205
• Web: arcellx.com
• Phone: 240-327-0603
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Arcellx: $110.36
• High Price Target: $120.00
• Low Price Target: $82.00
• Potential Upside/Downside: -4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.06
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$228.93 million
• Net Margins: -1,027.26%
• Pretax Margin: -1,026.94%
• Return on Equity: -55.42%
• Return on Assets: -36.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.44
• Quick Ratio: 4.44

Sales & Book Value

• Annual Sales: $22.29 million
• Price / Sales: 301.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.96 per share
• Price / Book: 16.53

Miscellaneous

• Outstanding Shares: 58,480,000
• Free Float: 53,597,000
• Market Cap: $6.73 billion
• Optionable: Optionable
• Beta: 0.25